Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study
Authors' conclusion
In participants with type 2 diabetes and albuminuria, treatment with dapagliflozin, exenatide and dapagliflozin-exenatide reduced albuminuria, with a numerically larger reduction in the combined dapagliflozin-exenatide treatment group.
Study context
- Population
- Patients with T2D, estimated glomerular filtration rate (eGFR) >30 ml/min/1.73m2 and UACR >3.5 mg/mmol and ≤100 mg/mmol53 treatment periods completed
- Participants
- 20 patients
- Comparison
- Dapagliflozin vs exenatide vs dapagliflozin-exenatide
- Primary endpoint
- Percentage change in UACR
Methodological detailscross-over, three 6-week treatment periods, random order
- Cross-over
- Three 6-week treatment periods
- Random order
Primary result
As reported in the abstract
Mean percentage change in UACR from baseline
Dapagliflozin
−21.9%
mean · 95% CI −34.8%–-6.4%
Exenatide
−7.7%
mean · 95% CI −23.5%–11.2%
Dapagliflozin-exenatide
−26.0%
mean · 95% CI −38.4%–-11.0%
Secondary outcomes
No correlation in albuminuria responses between treatments
- No correlation was observed in albuminuria responses between the different treatments
Renal haemodynamics (MRI): renal blood flow, effective renal plasma flow (ERPF), filtration fraction
- Filtration fraction change with dapagliflozin-exenatide
- −1.6% (95% CI: −3.2% to −0.01%); P = .048
- Renal blood flow and ERPF did not significantly change with either treatment regimen
- All but four and two patients in the dapagliflozin and dapagliflozin-exenatide groups, respectively, showed reductions in ERPF
- Filtration fraction did not change with dapagliflozin or exenatide
Systolic BP, body weight and eGFR
- Numerically greater reductions in systolic BP, body weight and eGFR with dapagliflozin-exenatide vs dapagliflozin or exenatide alone
Original publication
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study. Diabetes Obes Metab. Published 13 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →